Sentien Biotechnologies

Brian Miller, Co-Founder and CEO
Lexington, MA
Sentien Biotechnologies is a privately-held, clinical-stage company developing novel ex-vivo cell therapy applications to treat conditions caused by systemic, immune-mediated inflammation. Sentien’s lead product, SBI-101, integrates allogeneic mesenchymal stromal cells (MSCs) within an extracorporeal, hollow-fiber device. By immobilizing MSCs within a blood-filtration device, SBI-101 allows prolonged exposure of patient blood to the MSCs, resulting in the dynamic delivery of MSC-secreted factors at doses that are unattainable by direct injection. SBI-101 is being evaluated in a Phase Ib/IIa study in subjects with dialysis-requiring acute kidney injury. An interim readout from the study provides evidence of anti-inflammatory and wound healing effects consistent with the SBI-101 therapeutic hypothesis. Building on this therapeutic hypothesis, SBI-101 is being pursued in COVID-19 patients suffering from severe systemic inflammation. Sentien’s technology can be applied to additional systemic inflammatory indications in both acute and chronic diseases, focusing on complex conditions where an advanced therapeutic may offer compelling advantages.

By using this website you agree to accept our Privacy Policy and Terms & Conditions